Low-dose estradiol spray to treat vasomotor symptoms: A randomized controlled trial

Obstetrics and Gynecology

Volumn 111, Issue 6, 2008, Pages 1343-1351

  Buster, John E ^a   Koltun, William D ^b   Pascual, Maria Luz G ^b   Day, Wesley W ^b   Peterson, Craig ^b  

^a BROWN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; PLACEBO;

ADULT; AEROSOL; ARTHRALGIA; ARTICLE; BACKACHE; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HOT FLUSH; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; TREATMENT OUTCOME; VASOMOTOR DISORDER; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; PHASE 3 CLINICAL TRIAL;

ADMINISTRATION, CUTANEOUS; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 47749132361     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318175d162     Document Type: Article

References (22)

1. Minkin MJ. Considerations in the choice of oral vs. transdermal hormone therapy: a review. J Reprod Med 2004;49: 311-20.
2. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8 suppl:3-63.
3. Schmidt JW, Wollner D, Curcio J, Riedlinger J, Kim LS. Hormone replacement therapy in menopausal women: past problems and future possibilities. Gynecol Endocrinol 2006; 22:564-77.
4. Post MS, van der Mooren MJ, van Baal WM, Blankenstein MA, Merkus HM, Kroeks MV, et al. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study. Am J Obstet Gynecol 2003;189: 1221-7.
5. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-5.
6. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80.
7. Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;109:588-96.
8. Naunton M, Al Hadithy A, Brouwers JR, Archer DF. Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women. Menopause 2006; 13: 517-27.
9. Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;110:771-9.
10. Hossain M, Quebe-Fehling E, Sergejew T, Schmidt G, Skerjanec A, Ibarra de Palacios P, et al. Dose proportionality study of four doses of an estradiol transdermal system, Estradot. Maturity 2003;46:173-85.
11. North American Menopause Society. Estrogen and progestogen use in peri-and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007;14:168-82.
12. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause 2004;11:11-33.
13. Lobo RA. The rationale for low-dose hormonal therapy. Endocrine 2004;24:217-21.
14. Ettinger B. Vasomotor symptom relief versus unwanted effect: role of estrogen dosage. Am J Med 2005; 118 suppl:74-8.
15. Center for Drug Evaluation and Research. Guidance for industry: noncontraceptive estrogen drug products for the treatment of vasomotor symptoms and vulvar and vaginal atrophy symptoms-recommended prescribing information for health care providers and patient labeling. Nov Labeling Revision 4 (draft). Rockville (MD): US Department of Health and Human Services, Food and Drug Administration; 2005.
16. Ibarra de Palacios P, Schmidt G, Sergejew T, Quebe-Fehling E, Lockhart L, Krinsky L. Comparative study to evaluate skin irritation and adhesion of Estradot and Climara in healthy postmenopausal women. Climacteric 2002;5:383-9.
17. Vivus, Inc. Evamist (estradiol transdermal spray) product label approved by the U.S. Food and Drug Administration. Available at: http://www.fda.gov/cder/ foi/label/2007/0220141bl. pdf. Retrieved on February 22, 2008.
18. Center for Drug Evaluation and Research. Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms - recommendations for clinical evaluation Jan (draft). Rockville (MD): US Department of Health and Human Services, Food and Drug Administration; 2003.
19. Greene J. Constructing a standard climacteric scale. Maturitas 1998;29:25-31.
20. Buch A, Shen L, Kelly S, Sahota R, Brezovic C, Bixler C, et al. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara. Menopause 1998;5:107-12.
21. Agresti A. Categorical Data Analysis. 1st ed. New York (NY): John Wiley & Sons, Inc.; 1990.
22. Longcope C. Hormone dynamics at the menopause. Ann N Y Acad Sci 1990;592:21-30.